Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Penumbra, Inc. (PEN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that together outline Penumbra’s financial condition, major corporate events and obligations as a NYSE-listed issuer.
Among the most significant recent filings is a Form 8-K dated January 15, 2026, in which Penumbra reports entry into an Agreement and Plan of Merger with Boston Scientific Corporation and a Boston Scientific subsidiary. The filing describes the structure of the merger consideration, the mix of cash and Boston Scientific common stock, and the conditions required for closing. It also states that, if the merger is consummated, Penumbra’s securities will be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934 as promptly as practicable after the effective time.
Other Form 8-K filings highlighted here include results of operations and financial condition for specific quarters, where Penumbra furnishes earnings press releases as exhibits. These filings discuss revenue growth, gross margin, operating margin and the use of non-GAAP measures such as constant currency revenue, non-GAAP income from operations and adjusted EBITDA. The company explains how these non-GAAP metrics are calculated and why management considers them useful for assessing underlying business performance.
Additional 8-Ks address corporate governance and leadership changes, such as the appointment of a new company president and related compensation arrangements. These filings provide detail on board and executive decisions, equity awards and related person transactions, all within the framework of SEC disclosure requirements.
Through this page, users can follow Penumbra’s formal reporting on material events, financial results and the proposed merger with Boston Scientific. Stock Titan’s platform associates each filing with AI-powered summaries designed to explain the core points of lengthy documents, helping readers quickly understand items such as merger terms, earnings highlights, and key governance changes without having to parse every line of the underlying text.
For deeper research, investors can review the full text of Penumbra’s 10-K and 10-Q reports via the SEC’s EDGAR system, while using the summaries and context on this page as a guide to the most important disclosures affecting PEN and its anticipated transition to a wholly owned subsidiary of Boston Scientific.
Penumbra Inc. executive reports small stock sale under trading plan
Penumbra Inc.'s EVP, General Counsel & Secretary, Johanna Roberts, reported selling 1,800 shares of the company's common stock on 11/25/2025. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to trade shares according to a set schedule. The weighted average sale price was $300.06 per share, with individual trades executed between $300.00 and $300.54.
After this transaction, Roberts beneficially owns 64,736 shares of Penumbra common stock, and a portion of these shares remains subject to vesting, meaning they will be earned over time based on continued service or other conditions.
Penumbra Inc. (PEN) director Arani Bose reported recent changes in his holdings of the company’s common stock. On 11/25/2025, an affiliate entity, Bose Family Holdings II, LLC, sold 7,500 shares of Penumbra common stock at a weighted average price of $300.19 per share, executed under a pre-arranged Rule 10b5-1 trading plan. On 11/26/2025, the reporting person made a bona fide gift of 1,799 shares with no payment in consideration. Following these transactions, the filing shows 273,462 shares of Penumbra common stock held indirectly through Bose Family Holdings II, LLC and an additional 558 shares, a portion of which is subject to vesting.
Penumbra Inc. (PEN) director Arani Bose reported share sales in the company’s stock. On 11/21/2025, an indirect ownership vehicle sold 7,338 shares of Penumbra common stock at a weighted average price of $290.55, followed by a sale of 162 shares at a weighted average price of $291.09. The sales were made under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a preset schedule.
After these transactions, the reporting person beneficially owned 282,761 shares of Penumbra common stock indirectly through Bose Family Holdings II, LLC. A portion of the reported shares is subject to vesting, meaning some shares may become fully owned over time based on conditions such as continued service or performance.
Penumbra, Inc. (PEN) insider sale notice: A holder intends to sell 2,100 shares of Penumbra common stock on the NYSE through J.P. Morgan Securities LLC. The notice lists 39,162,197 common shares outstanding and an approximate sale date of 11/25/2025.
The 2,100 shares were acquired from the issuer on 12/28/2022 through an option exercise paid in cash. Over the past three months, the same seller has completed three separate sales of 600 Penumbra common shares each, on 09/02/2025, 10/01/2025, and 11/10/2025, with disclosed gross proceeds for each transaction.
By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Penumbra’s current or prospective operations.
Penumbra (PEN) filed a Form 144 notice for a planned secondary sale of common stock. A shareholder intends to sell 30,000 shares of Penumbra common stock through J.P. Morgan Securities LLC on the NYSE, with an aggregate market value of
Penumbra Inc. reported insider equity activity by its Chief Financial Officer, Maggie Yuen. On November 17, 2025, she was granted 3,580 restricted stock units (RSUs) under Penumbra's Amended and Restated 2014 Equity Incentive Plan. One quarter of these RSUs will vest each year on November 15, beginning in 2026, subject to her continued service.
On November 15, 2025, Penumbra withheld 364 shares of common stock and separately 327 shares to cover tax withholding obligations related to vesting RSUs. After these transactions and the new grant, Yuen beneficially owned 16,556 shares of Penumbra common stock directly.
Penumbra, Inc. (PEN) reported an insider equity transaction involving its President, Shruthi Narayan. On 11/15/2025, the company withheld 358 shares of common stock at a price of $280.07 per share. These shares were withheld to cover tax obligations that arose when previously granted restricted stock units vested.
After this tax withholding transaction, Narayan beneficially owned 26,603 shares of Penumbra common stock in direct ownership, and a portion of these shares remains subject to vesting. The filing is a routine disclosure of equity compensation and related tax withholding rather than an open-market purchase or sale.
Penumbra, Inc. (PEN)November 15, 2025, the company withheld 346 and 506 shares of common stock at $280.07 per share to cover tax obligations tied to vesting restricted stock units (RSUs). On November 17, 2025, Shiu received a grant of 3,580 RSUs under Penumbra's Amended and Restated 2014 Equity Incentive Plan, which will vest in four equal annual installments beginning on November 15, 2026, subject to continued service. After these transactions, Shiu beneficially owned 35,565 Penumbra shares directly, including shares subject to vesting, plus 300 shares held indirectly through a spouse's IRA.
Penumbra, Inc. executive Johanna Roberts, EVP, General Counsel & Secretary, reported equity transactions in the company’s common stock. On November 15, 2025, a total of 701 shares of common stock were withheld by Penumbra to cover tax obligations tied to vesting restricted stock units (RSUs), reducing her directly held shares to 62,956. On November 17, 2025, she received a grant of 3,580 RSUs under Penumbra’s Amended and Restated 2014 Equity Incentive Plan at a price of $0, bringing her directly beneficially owned common stock to 66,536 shares, a portion of which remains subject to vesting. One quarter of the new RSU grant is scheduled to vest annually beginning on November 15, 2026, conditioned on continued service.
Penumbra (PEN) reported insider transactions by its EVP, General Counsel & Secretary. On 11/10/2025, the officer sold small blocks of common stock in multiple open‑market trades executed under a Rule 10b5-1 trading plan. Weighted average sale prices by lot ranged from $263.58 to $269.56. Following these sales, the reporting person beneficially owned 63,657 shares directly. A portion of these shares is subject to vesting.